A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Recruiting now · Phase 2

Conditions studied: Immune Thrombocytopenia, Treatment

In brief

To evaluate the safety and efficacy of zanubrutinib in the treatment of immune thrombocytopenia in 30 patients.

Key facts

Study ID: NCT05214391
Run by: Institute of Hematology & Blood Diseases Hospital, China
People needed: 30
Starts: 2022-02-15
Expected to finish: 2025-12-31
Last updated by the study team: 2025-02-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 18 and above, male or female；
Conform to the diagnostic criteria of immune Thrombocytopenia (ITP)；
Diagnosis of ITP>3 months；
Primary ITP with a platelet count of <30 X 109/L prior to inclusion with failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy including rituximab >12 weeks ago and/or TPO-RAs.
Liver and kidney function, such as ALT, AST, BUN, SCR < 1.5 × upper limit of normal value, passing physical examination;
ECOG physical state score ≤ 2 points；
Cardiac function of the New York Society of Cardiac Function ≤ 2；
Signed and dated written informed consent.

You may not qualify if…

Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases;
HIV positive;
Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive;
Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc.;
At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled;
Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis;
Those who have received allogeneic stem cell transplantation or organ transplantation in the past;
Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up;
Patients whose toxic symptoms caused by pre-trial treatment have not disappeared;
Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.);
Patients with septicemia or other irregular severe bleeding;
Patients taking antiplatelet drugs at the same time;
Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients.

Where it is running

Chinese Academy of Medical Science and Blood Disease Hospital — Tianjin, Tianjin Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.